



Published in final edited form as:

Trends Pharmacol Sci. 2024 January ; 45(1): 24–38. doi:10.1016/j.tips.2023.11.002.

The rise of epitranscriptomics: recent developments and future directions

Jonas Cerneckis^{1,2}, Guo-Li Ming³, Hongjun Song^{4,*}, Chuan He⁵, Yanhong Shi^{1,2,*}

¹Department of Neurodegenerative Diseases, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

²Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.

³Department of Neuroscience and Mahoney Institute for Neurosciences, Department of Cell and Developmental Biology, Department of Psychiatry, Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

⁴Department of Neuroscience and Mahoney Institute for Neurosciences, Department of Cell and Developmental Biology, the Epigenetics Institute, Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

⁵Department of Chemistry, Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics, Howard Hughes Medical Institute, The University of Chicago, Chicago, IL 60637, USA.

Abstract

The epitranscriptomics field has undergone tremendous growth since the discoveries that the RNA *N*⁶-methyladenosine modification is reversible and ubiquitously distributed throughout the transcriptome. Efforts to map RNA modifications transcriptome-wide and reshape the epitranscriptome in disease settings have facilitated mechanistic studies and drug discovery in the field. In this review, we discuss recent advancements in RNA modification detection methods and consider how these developments can be applied to gain novel insights into the epitranscriptome. We also highlight drug discovery efforts aimed at developing epitranscriptomic therapeutics for cancer and other diseases. Finally, we consider engineering of the epitranscriptome as an emerging direction to investigate RNA modifications and their causal effects on RNA processing at high specificity.

*Correspondence: shongjun@pennmedicine.upenn.edu; yshi@coh.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of Interests

C.H. is a scientific founder and a member of the scientific advisory board of Accent Therapeutics Inc.

Keywords

*N*⁶-methyladenosine; RNA modifications; pseudouridine; epitranscriptomics; nanopore sequencing; drug development; machine learning

The rise of epitranscriptomics

That RNA molecules are decorated with modified nucleotides, or RNA modifications, has been known since the 1950s[1]. Early characterization of highly abundant RNA species, such as ribosomal RNA (rRNA) and transfer RNA (tRNA), revealed extensive post-transcriptional modification of these RNAs required to support their higher-order structure[2, 3]. However, the lack of methods to detect and map RNA modifications occurring on low abundance RNAs and their elusive functional relevance had rendered the field of epitranscriptomics dormant for several decades. In 2011, the discovery that an internal RNA modification *N*⁶-methyladenosine (*m*⁶A) was installed reversibly, and that the fat mass and obesity-associated protein (FTO) mediated its removal revealed the potential dynamic nature of *m*⁶A modification and hinted at its functional relevance[4].

Efforts to characterize the distribution, dynamics, and roles of *m*⁶A have since followed, propelling the field of epitranscriptomics into the limelight[5]. Sophisticated protocols for high-throughput profiling of RNA modifications have been developed and revealed ubiquitous and dynamic distribution of *m*⁶A and other internal RNA modifications across the transcriptome[5-7]. Today, it is well-established that over 170 types of RNA modifications dynamically decorate different RNA species and regulate almost every aspect of RNA metabolism[8]. In addition to *m*⁶A, modifications such as pseudouridine (Ψ), *N*¹-methyladenosine (*m*¹A), 5-methylcytosine (*m*⁵C) and others, are widespread on RNA and have been under intense investigation in recent years[5]. Importantly, aberrant expression of RNA modification machinery and dysregulation of the epitranscriptome in cancer have been exploited to develop novel therapeutic agents that could reverse modification-dependent pro-tumorigenic gene expression programs[9]. Streamlined detection of RNA modifications has also facilitated the study of epitranscriptomics in complex biological processes, such as human development, homeostasis, and diseases other than cancer. Overall, expansive growth and significance of epitranscriptomics have culminated in the 2023 Nobel Prize in Physiology or Medicine being awarded to the Hungarian-American biochemist Katalin Karikó and the American immunologist Drew Weissman for their discoveries that RNA modifications suppress messenger RNA (mRNA) immunogenicity and promote its translation[10-12]. These findings have critically contributed to the development of highly effective mRNA-based vaccines against coronavirus disease 2019 (COVID-19) [12].

In this review, we discuss key developments in the epitranscriptomics field, including the advancements in transcriptome-wide modification detection methods and drug discovery efforts. With a focus on the most-studied RNA modification, *m*⁶A, we consider the biological insights gained from mapping RNA modifications transcriptome-wide at varying resolution and identify the areas that are yet to be explored using recently developed

technologies. We also discuss drug discovery focused on epitranscriptomics, including various strategies and tools that have been implemented to develop novel therapeutic agents that target different epitranscriptomic components. Finally, we highlight RNA modification engineering as a powerful approach to characterize functional relevance of the epitranscriptome at a much higher specificity than is possible by modifying the expression or activity of the RNA modification machinery.

Advancements in transcriptome-wide detection of RNA modifications

RNA modifications can be characterized in different aspects, such as their location and distribution across the transcriptome, dynamics in response to changing cellular or environmental conditions, heterogeneity across different cells and tissues, and stoichiometry (see **Glossary**). Each of these characteristics can provide distinct insights into the roles of the epitranscriptome in RNA processing and cellular biology. Continuous advancements in methods for mapping RNA modifications have been the driving force of scientific discovery in the field, enabling the characterization and functional relevance of RNA modifications to be elucidated.

Location and distribution of RNA modifications

The discovery that m⁶A was installed reversibly and identification of its dedicated modification machinery (see Box 1) were major clues that m⁶A played regulatory roles in RNA processing[4, 5, 13, 14]. However, determining how ubiquitous and dynamic the m⁶A methylome is and whether it can influence global RNA biology requires reliable transcriptome-wide approaches for mapping m⁶A. The first transcriptome-wide m⁶A modification landscapes were obtained by RNA immunoprecipitation-based m⁶A detection (MeRIP-seq and m⁶A-seq protocols) using m⁶A-specific antibodies in 2012 (see Figure 1A) [15, 16]. These studies have revealed that m⁶A decorates multiple RNA species, whereas the global m⁶A landscape changes dynamically in response to changing cellular conditions[15, 16]. Notably, antibody-based m⁶A detection remains the most commonly used and facile approach to map m⁶A today.

One important limitation of MeRIP-seq and m⁶A-seq protocols is their limited resolution because m⁶A-decorated RNA is enriched as 100–200 nucleotide-long fragments[6, 17]. Therefore, subsequently developed protocols for mapping m⁶A have been aimed at achieving single-nucleotide resolution, so that individual m⁶A sites could be identified. Cross-linking of m⁶A-specific antibodies to RNA has improved resolution of antibody-based m⁶A detection protocols because a mutational signature is introduced around the m⁶A site during reverse transcription and can be used to infer the position of m⁶A[18, 19]. Several methods for introducing mutations at the m⁶A site without the use of m⁶A-specific antibodies have also been developed. For example, enzymatic deamination at sites adjacent to RNA modification targets (DART-seq) is based on the recruitment of a cytidine deaminase APOBEC1 to m⁶A-decorated sites via a fused m⁶A reader YTH domain, leading to C-to-U conversion in the vicinity of m⁶A residues (Figure 1B)[20]. Chemical and metabolic labeling of m⁶A can also be used to introduce mutations or deletions at the m⁶A site or enrich m⁶A-decorated RNA (Figure 1C)[21–23]. For example, the m⁶A-SAC-seq protocol

is based on enzymatic labeling of m⁶A sites by a dimethyltransferase MjDim1 followed by chemical modification, which leads to incorporation of a mutational signature during reverse transcription[21]. An m⁶A-sensitive RNase MazF that cleaves RNA at ACA motifs but fails to do so in the presence of m⁶A has also been applied to map m⁶A (Figure 1D)[24, 25]. Mapping of m⁶A at single-nucleotide resolution has generated comprehensive maps of the m⁶A methylome that will serve as a rich resource for future mechanistic studies. Concurrently, protocols for antibody- and labeling-based detection of other RNA modifications have been developed, enabling the study of the epitranscriptome beyond m⁶A[26].

Cellular heterogeneity of RNA modifications

Single-cell RNA sequencing (scRNA-seq) has revolutionized transcriptomic profiling, revealing immense spatiotemporal heterogeneity of gene expression in individual cells. Protocols that combine m⁶A detection methods and scRNA-seq, including scm⁶A-seq and scDART-seq, can be used to map m⁶A at single-cell resolution and uncover cellular heterogeneity of the m⁶A epitranscriptome[27, 28]. Single-cell profiling of m⁶A has revealed many lowly modified m⁶A sites that are only present in a subpopulation of cells as well as variable m⁶A stoichiometry across individual cells. Interestingly, these distinct m⁶A methylation patterns can be used to group cells into clusters based on the global m⁶A signature[27, 28]. More recently, simultaneous profiling of m⁶A and gene expression at single-nucleus resolution has been developed to probe the interplay between epitranscriptome and transcriptome[29]. Although the protocols for single-cell detection of RNA modifications are just emerging, we anticipate that future studies will reveal yet unappreciated spatiotemporal heterogeneity of the epitranscriptome across human development and diseases.

Stoichiometry of RNA modifications

Unlike DNA, RNA transcripts can be present in dozens or hundreds of copies in a single cell. RNA modification stoichiometry describes what fraction of these RNA copies is modified at a given time. Yet, the mechanisms of regulation and the functional relevance of modification stoichiometry are largely unknown. One way to quantify RNA modification stoichiometry is to include spike-in calibration probes modified at different levels into the modification detection pipeline, so that modification levels can be normalized during data analysis. Using m⁶A-SAC-seq with spike-in calibration, Hu *et al.* were able to document dynamic changes in m⁶A stoichiometry during hematopoietic stem and progenitor cell (HSPC) differentiation[21]. These changes in m⁶A stoichiometry were shown to be accompanied by alternative splicing events, indicating functional relevance of m⁶A stoichiometry[21]. Recently, eTAM-seq and GLORI protocols based on selective adenine but not m⁶A deamination were shown to achieve high adenine conversion, enabling quantification of m⁶A stoichiometry based on the ratio of intact (m⁶A) and deaminated adenines (Figure 1E)[30, 31]. Quantitative detection of m⁶A by deamination revealed a median methylation level of 40% across all m⁶A sites and its functional relevance: m⁶A stoichiometry is dynamic under changing cellular conditions and has a significant effect on translation efficiency of mRNA[30]. Protocols for stoichiometric quantification of other RNA modifications, especially Ψ, are also emerging. PRAISE[32] and BID-seq[33]

protocols for quantitative detection of Ψ are based on bisulfite-induced deletion and have revealed highly variable Ψ stoichiometry across different modification sites. Although biological relevance and regulatory mechanisms of RNA modification stoichiometry are yet to be elucidated, quantitative detection of RNA modifications is likely to reveal yet another layer of complexity of the epitranscriptome and facilitate new discoveries in the field.

Insights gained from third-generation sequencing approaches

Alongside next generation sequencing (NGS)-based protocols discussed above, third-generation sequencing approaches and machine learning play an increasingly important role in charting the epitranscriptome. Specifically, nanopore sequencing can be performed on native RNA, thus preserving RNA modifications during library preparation, and has been widely applied to detect m⁶A and other RNA modifications (Figure 1F)[34, 35]. In nanopore sequencing, computer algorithms are used to infer RNA modifications from various biophysical parameters recorded as the RNA molecule passes through the nanopore[34, 36]. Unsupervised learning algorithms, such as DRUMMER[37] and ELIGOS[38], are based on comparative analysis of test and modification-depleted control samples to infer RNA modifications between two conditions[34, 36]. Although comparative methods do not require training datasets, modification-depleted control samples can be challenging to prepare and increase the complexity of a given experiment. Alternatively, supervised learning algorithms, such as m6Anet[39] and DENA[40], are trained with labeled datasets and used to predict RNA modifications based on sequence-specific or genomic feature information[36]. Supervised learning can be applied to predict RNA modifications in unseen datasets and does not require preparation of control samples. Like NGS approaches, nanopore sequencing-based detection of RNA modifications has the potential to achieve single-nucleotide resolution and enable stoichiometric quantification[39]. Nanopore sequencing should also enable simultaneous detection of different RNA modifications because all modifications are preserved on native RNA. Indeed, a neural network-based algorithm CHEUI has recently been applied to infer m⁶A and m⁵C modifications simultaneously, revealing non-random co-occurrence of the two modifications[41]. It will be interesting to determine whether different RNA modifications can be installed in a coordinated manner and whether co-occurring RNA modifications have synergistic effects on downstream RNA processing.

Drug development focused on epitranscriptomics

Widespread adoption of high-throughput methods for mapping RNA modifications has revealed dysregulation of the epitranscriptome in human diseases, especially cancer[9, 42]. Subsequently, mechanistic studies have indicated that disease-associated phenotypes, such as tumor growth, can be reversed by manipulating the expression or activity of the RNA modification machinery[9, 42]. The motivation to uncover novel therapeutically targetable pathways of the epitranscriptome for treating human diseases has been another driving force in the epitranscriptomics field. Different strategies have emerged for drug discovery focused on epitranscriptomics, including manipulation of the RNA modification machinery, and targeting of RNA modification-dependent vulnerabilities in cancer and diseases other than cancer.

Targeting the RNA modification machinery

Tumor atlases[43, 44] have been instrumental in uncovering protein effectors of the RNA modification machinery that become dysregulated in cancer and play oncogenic roles (see Figure 2A)[1, 9]. Accordingly, small-molecule inhibitors can be developed to suppress the activity of oncogenic RNA modification machinery. Virtual drug screening is an efficient and cost-effective approach to screen drug libraries and has been applied to identify hit compounds targeting various protein effectors of the RNA modification machinery, including the m⁶A eraser FTO[45], the m⁶A reader insulin-like growth factor 2 mRNA binding protein (IGF2BP)2[46], and the Ψ writer pseudouridine synthase (PUS)7[47] (Figure 2B). Alternatively, classical drug screening using cell-free assays has been used to identify inhibitors of the m⁶A writer METTL3[48] and the m⁶A reader YTH N⁶-methyladenosine RNA binding protein (YTHDF)2[49]. Cell-free assays are also often used to validate the inhibitory activity of the identified hit compounds (Figure 2C). For example, *in vitro* RNA m⁶A methylation and demethylation assays have been used to evaluate METTL3[48] and FTO[45, 50, 51] inhibitors, respectively. Target selectivity and pharmacokinetics of therapeutic candidates can be further improved by rational drug design, as exemplified by chemical optimization of METTL3[52] and FTO[50, 51, 53] inhibitors (Figure 2D).

Having identified and optimized hit compounds targeting the RNA modification machinery, their effects on cancer cell growth and tumor progression can be assessed *in vitro* and *in vivo*. In addition to standard *in vitro* cell proliferation assays, limiting dilution analysis can be performed to evaluate cancer stem cell activity that is often affected by the dysregulated epitranscriptome (Figure 2E)[45-47, 53, 54]. *In vivo* models enable evaluation of pharmacokinetics, immune cell infiltration, and other aspects of tumor progression that cannot be evaluated *in vitro* (Figure 2F). For example, Su *et al.* found that an FTO inhibitor CS1 robustly suppressed proliferation of leukemia cells *in vitro*, but it exhibited low efficacy *in vivo* due to its limited bioavailability[45]. To overcome the hydrophobicity of CS1 and promote its uptake, the authors packaged CS1 into polyethylene glycol-poly lactide (PEG-PLA) micelles or coated CS1 with β-cyclodextrin, which substantially improved CS1 uptake and anti-leukemic activity *in vivo*[45]. *In vivo* models have also revealed synergistic effects of epitranscriptomic drugs and cancer immunotherapy; for example, pharmacological inhibition of YTHDF2[49] or FTO[51] synergizes with anti-PD-L1 immunotherapy and limits tumor immune evasion. Overall, efforts to develop drugs that target the RNA modification machinery have resulted in a new class of epitranscriptomic therapeutics that hold promise to alleviate cancer burden in patients.

Targeting RNA modification-dependent tumor vulnerabilities

An alternative approach for therapeutic development in the epitranscriptomics field is to identify tumor vulnerabilities based on modification-dependent dysregulation of gene expression. This approach entails a comparative analysis of the epitranscriptome and gene expression between cancer cells and healthy control tissues to identify cellular pathways that are dysregulated in cancer because of modification-dependent changes in gene expression. For example, Lv *et al.* found that m⁶A methylation of *OPTN* mRNA, encoding a mitophagy regulator optineurin, was increased in glioblastoma stem cells, promoting

OPTN degradation and dysregulation of mitophagy[55]. Pharmacological inhibition of METTL3 and mitophagy synergistically suppressed glioblastoma progression *in vivo* and prolonged survival, revealing the METTL3-mitophagy axis as a potential therapeutic target in glioblastoma[55]. Identification of modification-dependent tumor vulnerabilities is thus reliant on accurate transcriptome-wide detection of RNA modifications, highlighting the importance of continuously advancing RNA modification detection methods for therapeutic development in the field. RNA modification databases, such as MODOMICS[8], m⁶A Atlas[56], and the m⁶A-centered regulation of disease development and response database (M6AREG)[57], also facilitate mechanism-driven drug discovery by enabling data compilation and sharing (Figure 2A). Finally, machine learning can be applied to process large-scale omics data to uncover hidden crosstalk between distant pathways and predict novel targets involved in the regulation of the epitranscriptome to accelerate therapeutic development[58-60].

Therapeutic development for diseases other than cancer

Although drug development for targeting dysregulated RNA modification machinery or modification-dependent vulnerabilities has been mostly focused on cancer, the expanding mechanistic understanding of epitranscriptomics paves the way for developing epitranscriptomic therapies to treat various other human diseases. Accumulating evidence of epitranscriptomic dysregulation in cardinal human diseases, such as diabetes, heart disease and neurodegeneration, indicates the potential for targeting dysfunctional pathways to restore tissue homeostasis[61]. Furthermore, the knowledge of functional implications of RNA modifications has already been applied to derive remarkably effective mRNA-based vaccines against COVID-19[12]. In particular, incorporation of a modified Ψ (*N*¹-methylpseudouridine) into *in vitro*-transcribed mRNA vaccines has been pivotal in circumventing the intrinsic immunogenicity of unmodified mRNA and ensuring success of these vaccines against COVID-19, building on decades of research into RNA modifications[10, 11, 62]. With the immunogenicity hurdle of mRNA-based vaccines finally overcome, it can be expected that such vaccines will be developed against other infectious[63] and, potentially, chronic diseases. Future work may also reveal how RNA modifications can be used to improve the stability of mRNA vaccines and prolong their shelf-life.

Engineering the epitranscriptome for mechanistic studies

Dysregulation of the RNA modification machinery in human cancers has enabled relatively straightforward investigation of these protein effectors: experimental manipulation of their expression can be used to determine whether a specific protein acts as an oncogene or a tumor suppressor[9, 42]. However, perturbation of a protein effector, such as the m⁶A writer METTL3, results in changes of hundreds to thousands of modification sites, making it challenging to decipher the effects of individual modification sites on phenotypic outcomes. Furthermore, RNA modifications play regulatory roles in various biological processes, such as human brain development and function (see Box 2), that do not necessarily involve dysregulation of the RNA modification machinery but rather depend on correct gene expression programs modulated by the epitranscriptome. Defining causal

effects of RNA modifications on RNA processing and downstream phenotypic outcomes thus necessitates targeted manipulation of modification sites, which can be achieved by introducing point mutations into the primary DNA sequence. However, targeted mutagenesis is a laborious process that cannot recapitulate important features of RNA modification, such as its reversibility or stoichiometric information. Alternative approaches for inducible and reversible manipulation of individual RNA modification sites are highly desired to uncover specific roles of these chemical moieties and facilitate the next phase of modification-focused scientific discovery in the epitranscriptomics field. In this section, we discuss epitranscriptomic engineering as an emerging approach to manipulate RNA modifications in a targeted manner. We highlight state-of-the-art molecular tools used for engineering the epitranscriptome, their applications in mechanistic studies, and associated challenges.

Molecular tools for engineering RNA modifications and their applications

The development and rapid adaptation of CRISPR/Cas technology have enabled versatile genetic engineering by targeted recruitment of a Cas endonuclease using a sequence-specific single guide RNA (sgRNA)[64]. Catalytically inactive Cas proteins (dCas) can be used to recruit other protein modalities to the desired genomic loci without introducing DNA strand breaks[65]. Similarly, RNA-targeting dCas13 can be fused to various protein effectors that modify RNA, thus enabling RNA modification engineering (see Figure 3A)[66, 67]. In this way, RNA modifications can be introduced or removed at specific sites without the need for mutating the primary DNA sequence. Indeed, successful targeted installation and erasure of m⁶A using dCas13-METTL3 and dCas13-ALKBH5, respectively, have been reported[68-70]. Similarly, dCas13 fused to a deaminase domain of adenosine deaminase acting on RNA type 2 (ADAR2) can induce targeted A-to-I RNA editing[67, 71]. RNA can also be targeted using dCas9 if a single-stranded DNA molecule containing a protospacer adjacent motif (PAM) is supplied, an approach that has been applied to write and erase m⁶A[72-74]. In addition to CRISPR-based molecular tools, endogenous RNA modification machinery can be recruited by providing a sequence-specific guide RNA. For example, two groups have recently demonstrated that endogenous pseudouridylation machinery can be recruited to install Ψ on desired RNA transcripts (Figure 3B)[75, 76]. Furthermore, endogenous ADAR proteins can be recruited for A-to-I editing by supplying exogenous circular guide RNA[77]. Molecular tools can also be tailored to achieve temporal control of RNA modification engineering. For example, Shi *et al.* developed a system for inducible m⁶A modification, where the release of photo-caged abscisic acid upon UV light exposure is required for tethering dCas13 with METTL3 or ALKBH5 via adaptor proteins (Figure 3C)[78]. We anticipate that the toolkit for RNA modification engineering will continue to expand as our understanding of diverse RNA modifications and their modification machinery advances.

RNA modification engineering studies have revealed causal effects of RNA modifications on RNA processing, including splicing[69, 70], nuclear export[70], interaction with RNA-binding proteins[74], and stability[68, 69] of RNA transcripts (Figure 4A, **Key Figure**). For example, targeted methylation of an alternatively spliced exon of the *Brd8* mRNA promotes exon skipping, whereas targeted methylation of the *Actb* mRNA leads to a substantial decrease (up to 70%) in *Actb* mRNA levels[69]. These findings indicate that

even individual m⁶A sites have a major influence on RNA processing and stability. Engineering Ψ at premature termination codons (PTCs) leads to PTC-read-through and translation of the full-length protein, confirming the role of Ψ in PTC suppression[75, 76]. Importantly, RNA engineering can reveal causal relationships between RNA modifications and human diseases. Targeted m⁶A methylation of *CDCP1* mRNA promotes translation of the CUB domain-containing protein (CDCP)1 and progression of bladder cancer (Figure 4A)[72]. Furthermore, correcting the W437X mutation of the PTEN-induced kinase (PINK)1 implicated in Parkinson's disease by targeted A-to-I editing rescues impaired mitophagy[79]. Therefore, RNA modification engineering can be applied to model modification-dependent disease phenotypes and establish causal relationships between the epitranscriptome and disease-associated phenotypes.

In addition to engineering RNA modifications, targeted recruitment of reader proteins can be used to study their roles in downstream processing of modified RNAs (Figure 4B). Targeted recruitment of YTHDF1 and YTHDF2 promotes mRNA translation and degradation, respectively, reflecting the roles of these m⁶A readers documented in other studies[80]. Furthermore, tagging dCas13 with green fluorescent protein (GFP) enables live tracking of modified transcripts, which can be applied to clarify the roles of RNA modification reader proteins in RNA localization and trafficking[66]. For example, YTHDF proteins have been proposed to guide m⁶A-decorated mRNAs into stress granules, but this observation remains controversial and requires further investigation[81-83]. Similarly, tracking RNA dynamics in cells that depend on highly orchestrated RNA trafficking, such as neurons, may reveal the roles of RNA modifications and reader proteins in complex biological processes, such as synaptogenesis (Figure 4B). The roles of reader proteins in the onset and progression of human diseases can also be clarified using molecular tools for tracking these protein effectors and modified RNA.

The RNA modification engineering tools described above can be packaged into adeno-associated virus (AAV) vectors for delivery *in vivo* (Figure 4C)[84]. RNA modification engineering *in vivo* will facilitate the study of complex phenotypes that cannot be modeled *in vitro*, such as synaptic plasticity, learning, and memory. M⁶A has been shown to enhance translation and promote learning and memory in response to neuronal stimulation[85], but the exact RNA modification-dependent mechanisms of synaptic plasticity remain to be elucidated. Similarly, the effects of individual RNA modifications on tumor growth, metastasis, and tumor immune microenvironment can be assessed *in vivo*. Finally, *in vivo* models can be used to evaluate clinical relevance of RNA modification engineering, given its potential to reverse disease-associated phenotypes[72, 76, 79].

Challenges and limitations of RNA modification engineering

Although RNA modification engineering is a powerful approach to pinpoint individual contributions of RNA modifications to RNA biology, challenges associated with this technology should be carefully considered. These include off-target activity and on-target editing efficiency, complicated by the fact that RNA molecules are present in dozens of copies and undergo dynamic turnover. Transcriptome-wide detection of the RNA modification of interest will be required to assess off-target activity of RNA engineering

tools. Similarly, it remains unclear if endogenous modification stoichiometry can be reproduced using RNA engineering tools. On-target editing efficiency and the levels of the engineered modification can be assessed using targeted m⁶A-SAC-seq[86] or eTAM-seq[31] for m⁶A and BID-seq for Ψ[33]. The optimal footprint for modification engineering should also be considered; for example, Liu *et al.* reported a 10-nucleotide window for m⁶A engineering directed by a dCas9 fusion construct with METTL3/14 catalytic domains[74]. A narrow engineering window may be sufficient for editing individual modification sites, whereas recruitment of several units of the RNA modification machinery by peptide scaffolds may be needed to engineer m⁶A clusters. Finally, whether RNA modification engineering tools should be directed for nuclear or cytoplasmic localization and whether they physically interfere with RNA processing, such as translation, should be determined[87].

Concluding Remarks and Future Perspectives

The epitranscriptomics field has undergone explosive growth since the discovery that m⁶A is reversibly installed in 2011[4]. Continuously improving RNA modification detection methods have enabled in-depth mechanistic studies of the epitranscriptome, whereas drug screening and rational drug design strategies have yielded potent small-molecule inhibitors of the RNA modification machinery. Although mostly focused on m⁶A and cancer, these developments have harnessed substantial interest in the wider field of epitranscriptomics, prompting investigations into other RNA modifications and in the context of a multitude of complex biological processes of human development, homeostasis, and disease (Box 2).

As the field moves forward, increasing access to advanced technologies of mapping and engineering RNA modifications will be critical to gain new insights into modification-dependent regulation of RNA biology and downstream phenotypic outcomes (see Outstanding Questions). For example, defining the roles and regulation of recently described m⁶A clusters[30, 31] may reveal yet unappreciated interplay between individual RNA modifications and their concerted influence on downstream RNA processing. Likewise, the roles and interplay of less thoroughly examined modifications across different RNA species will further advance our understanding of RNA metabolism and regulation. Improvements in detection methods will facilitate mapping of RNA modifications at ever increasing resolution; for example, long-read nanopore sequencing may enable detection of RNA modifications at isoform resolution[36]. As exemplified by the TadA8.20 deaminase variant used in eTAM-seq, protein engineering by directed evolution will play an important role in the development of novel enzymes that selectively label various RNA modifications, aiding their detection[31, 88]. Refined maps of the epitranscriptome will, in turn, facilitate training of supervised learning algorithms to advance nanopore-based detection methods and *de novo* prediction of RNA modifications. Machine learning will also be instrumental in propelling cancer therapeutic development as it can be widely applied in target discovery and drug design efforts[59, 60, 89]. We anticipate that therapeutic strategies focused on the epitranscriptome will also be developed for human diseases other than cancer as our understanding of RNA modifications in complex biological processes continues to advance. Accessible mapping of RNA modifications combined with machine learning will drive the discovery of RNA modification-based tissue and blood biomarkers of human

diseases, especially cancer, to accelerate diagnosis and prognosis. Finally, the expanding toolkit of RNA modification engineering will enable precise examination of the mechanisms governing modification-dependent regulation of diverse biological processes with the focus on the RNA modification itself.

Acknowledgements

The authors would like to thank Louise and Herbert Horvitz, the Christopher Family, the Judy and Bernard Briskin Fund, and the Sidell Kagan Foundation for their generosity and forethought. This work was supported by the National Institute of Aging of the National Institutes of Health R01 AG072291 and RF1 AG079307 to Y.S., R35NS116843 to H.S., R35NS097370 and Dr. Miriam and Sheldon G. Adelson Medical Research to G.-I.M. J.C. is a predoctoral scholar in the Stem Cell Biology and Regenerative Medicine Research Training Program of the California Institute for Regenerative Medicine (CIRM). Figures 1-4 were created with BioRender.com.

Glossary

Directed evolution

a methodology to engineer desired traits of biological molecules by introducing random mutations and evaluating their effects on functionality. Directed evolution is often applied to improve enzyme activity or endow enzymes with novel functions.

Epitranscriptomics

a genetics field that encompasses RNA modifications and their function.

MeRIP-seq

a methodology for mapping m⁶A transcriptome-wide by immunoprecipitation of m⁶A-decorated RNA fragments followed by next-generation sequencing.

Machine learning

a field of computer science and artificial intelligence that encompasses computational techniques to perform a certain task without explicitly providing an algorithm.

m⁶A-SAC-seq

a methodology for mapping m⁶A by selective allyl chemical labeling of m⁶A sites followed by next-generation sequencing. During reverse transcription, a mutational signature is introduced at chemically labeled sites, enabling m⁶A detection.

Nanopore sequencing

a third-generation sequencing approach based on detection of ionic current changes when a nucleic acid strand passes through a biological pore. Nanopore sequencing can be performed on native nucleic acids, thus preserving nucleic acid modifications and enabling their direct detection.

Native RNA

in sequencing, “native” indicates that RNA has not been subject to copy DNA (cDNA) synthesis and polymerase chain reaction (PCR) during library preparation, and thus RNA modifications are preserved.

Omics

a term used to describe fields of biology, such as genomics, that encompass the entirety of a large-scale biological system, such as the genome.

Rational drug design

knowledge- and data-driven development of therapeutic candidates based on their chemical properties and interactions with a target.

Stoichiometry

in the context of RNA modifications, stoichiometry defines the level of modification at a given site across multiple copies of the same RNA transcript. For example, if 70 out of 100 molecules of a given mRNA transcript are m⁶A modified at a specified position, the level of m⁶A at that position is 70%.

Supervised learning

a type of machine learning that uses labeled data to train algorithms for outcome prediction or data classification of unseen datasets.

Tumor atlas

an assembly of large-scale omics data about different types and states of cancer.

Unsupervised learning

a type of machine learning that is used to analyze and classify unlabeled data.

Virtual drug screening

a computational approach to identify drug-like compounds that are likely to bind to a specific protein target.

References

1. Cerneckis J. et al. (2022) Decoding pseudouridine: an emerging target for therapeutic development. *Trends Pharmacol Sci* 43 (6), 522–535. [PubMed: 35461717]
2. Suzuki T. (2021) The expanding world of tRNA modifications and their disease relevance. *Nature Reviews Molecular Cell Biology* 22 (6), 375–392. [PubMed: 33658722]
3. Sloan KE et al. (2017) Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function. *RNA Biol* 14 (9), 1138–1152. [PubMed: 27911188]
4. Jia G. et al. (2011) N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. *Nat Chem Biol* 7 (12), 885–7. [PubMed: 22002720]
5. Roundtree IA et al. (2017) Dynamic RNA Modifications in Gene Expression Regulation. *Cell* 169 (7), 1187–1200. [PubMed: 28622506]
6. Helm M and Motorin Y (2017) Detecting RNA modifications in the epitranscriptome: predict and validate. *Nat Rev Genet* 18 (5), 275–291. [PubMed: 28216634]
7. Wiener D and Schwartz S (2021) The epitranscriptome beyond m(6)A. *Nat Rev Genet* 22 (2), 119–131. [PubMed: 33188361]
8. Boccaletto P. et al. (2022) MODOMICS: a database of RNA modification pathways. 2021 update. *Nucleic Acids Res* 50 (D1), D231–D235. [PubMed: 34893873]
9. Deng X. et al. (2023) The roles and implications of RNA m(6)A modification in cancer. *Nat Rev Clin Oncol* 20 (8), 507–526. [PubMed: 37221357]
10. Kariko K. et al. (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 23 (2), 165–175. [PubMed: 16111635]

11. Kariko K. et al. (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther* 16 (11), 1833–1840. [PubMed: 18797453]
12. Nance KD and Meier JL (2021) Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. *Acs Central Science* 7 (5), 748–756. [PubMed: 34075344]
13. Zheng G. et al. (2013) ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. *Mol Cell* 49 (1), 18–29. [PubMed: 23177736]
14. Wang X. et al. (2014) N6-methyladenosine-dependent regulation of messenger RNA stability. *Nature* 505 (7481), 117–120. [PubMed: 24284625]
15. Meyer KD et al. (2012) Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. *Cell* 149 (7), 1635–1646. [PubMed: 22608085]
16. Dominissini D. et al. (2012) Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. *Nature* 485 (7397), 201–206. [PubMed: 22575960]
17. Kong Y. et al. (2023) Navigating the pitfalls of mapping DNA and RNA modifications. *Nat Rev Genet* 24 (6), 363–381. [PubMed: 36653550]
18. Linder B. et al. (2015) Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. *Nat Methods* 12 (8), 767–772. [PubMed: 26121403]
19. Koh CWQ et al. (2019) Atlas of quantitative single-base-resolution N(6)-methyl-adenine methylomes. *Nat Commun* 10 (1), 5636. [PubMed: 31822664]
20. Meyer KD (2019) DART-seq: an antibody-free method for global m(6)A detection. *Nat Methods* 16 (12), 1275–1280. [PubMed: 31548708]
21. Hu L. et al. (2022) m(6)A RNA modifications are measured at single-base resolution across the mammalian transcriptome. *Nat Biotechnol* 40 (8), 1210–1219. [PubMed: 35288668]
22. Shu X. et al. (2020) A metabolic labeling method detects m(6)A transcriptome-wide at single base resolution. *Nat Chem Biol* 16 (8), 887–895. [PubMed: 32341503]
23. Wang Y. et al. (2020) Antibody-free enzyme-assisted chemical approach for detection of N(6)-methyladenosine. *Nat Chem Biol* 16 (8), 896–903. [PubMed: 32341502]
24. Zhang Z. et al. (2019) Single-base mapping of m(6)A by an antibody-independent method. *Sci Adv* 5 (7), eaax0250. [PubMed: 31281898]
25. Garcia-Campos MA et al. (2019) Deciphering the "m(6)A Code" via Antibody-Independent Quantitative Profiling. *Cell* 178 (3), 731–747 e16. [PubMed: 31257032]
26. Zhang Y. et al. (2022) Detection technologies for RNA modifications. *Exp Mol Med* 54 (10), 1601–1616. [PubMed: 36266445]
27. Tegowski M. et al. (2022) scDART-seq reveals distinct m(6)A signatures and mRNA methylation heterogeneity in single cells. *Mol Cell* 82 (4), 868–878 e10. [PubMed: 35081365]
28. Yao H. et al. (2023) scm(6)A-seq reveals single-cell landscapes of the dynamic m(6)A during oocyte maturation and early embryonic development. *Nat Commun* 14 (1), 315. [PubMed: 36658155]
29. Hamashima K. et al. (2023) Single-nucleus multiomic mapping of m(6)A methylomes and transcriptomes in native populations of cells with sn-m6A-CT. *Mol Cell*.
30. Liu C. et al. (2023) Absolute quantification of single-base m(6)A methylation in the mammalian transcriptome using GLORI. *Nat Biotechnol* 41 (3), 355–366. [PubMed: 36302990]
31. Xiao YL et al. (2023) Transcriptome-wide profiling and quantification of N(6)-methyladenosine by enzyme-assisted adenosine deamination. *Nat Biotechnol* 41 (7), 993–1003. [PubMed: 36593412]
32. Zhang M. et al. (2023) Quantitative profiling of pseudouridylation landscape in the human transcriptome. *Nat Chem Biol*, 1–11. [PubMed: 36280796]
33. Dai Q. et al. (2023) Quantitative sequencing using BID-seq uncovers abundant pseudouridines in mammalian mRNA at base resolution. *Nat Biotechnol* 41 (3), 344–354. [PubMed: 36302989]
34. Wang Y. et al. (2021) Nanopore sequencing technology, bioinformatics and applications. *Nat Biotechnol* 39 (11), 1348–1365. [PubMed: 34750572]
35. Zhao X. et al. (2022) Detecting RNA modification using direct RNA sequencing: A systematic review. *Comput Struct Biotechnol J* 20, 5740–5749. [PubMed: 36382183]

36. Acera Mateos P. et al. (2023) Concepts and methods for transcriptome-wide prediction of chemical messenger RNA modifications with machine learning. *Brief Bioinform* 24 (3), bbad163. [PubMed: 37139545]
37. Price AM et al. (2020) Direct RNA sequencing reveals m(6)A modifications on adenovirus RNA are necessary for efficient splicing. *Nat Commun* 11 (1), 6016. [PubMed: 33243990]
38. Jenjaroenpun P. et al. (2021) Decoding the epitranscriptional landscape from native RNA sequences. *Nucleic Acids Res* 49 (2), e7. [PubMed: 32710622]
39. Hendra C. et al. (2022) Detection of m6A from direct RNA sequencing using a multiple instance learning framework. *Nat Methods* 19 (12), 1590–1598. [PubMed: 36357692]
40. Qin H. et al. (2022) DENA: training an authentic neural network model using Nanopore sequencing data of Arabidopsis transcripts for detection and quantification of N(6)-methyladenosine on RNA. *Genome Biol* 23 (1), 1–23. [PubMed: 34980209]
41. Acera Mateos P. et al. Simultaneous identification of m6A and m5C reveals coordinated RNA modification at single-molecule resolution. Preprint in *BioRxiv*.
42. Barbieri I and Kouzarides T (2020) Role of RNA modifications in cancer. *Nat Rev Cancer* 20 (6), 303–322. [PubMed: 32300195]
43. (2020) The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. *Nature* 578 (7793), 82–93. [PubMed: 32025007]
44. Rozenblatt-Rosen O. et al. (2020) The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. *Cell* 181 (2), 236–249. [PubMed: 32302568]
45. Su R. et al. (2020) Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. *Cancer Cell* 38 (1), 79–96 e11. [PubMed: 32531268]
46. Weng H. et al. (2022) The m(6)A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. *Cancer Cell* 40 (12), 1566–1582 e10. [PubMed: 36306790]
47. Cui Q. et al. (2021) Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis. *Nat Cancer* 2 (9), 932–949. [PubMed: 35121864]
48. Yankova E. et al. (2021) Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. *Nature* 593 (7860), 597–601. [PubMed: 33902106]
49. Wang L. et al. (2023) YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. *Cancer Cell* 41 (7), 1294–1308 e8. [PubMed: 37236197]
50. Huang Y. et al. (2019) Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. *Cancer Cell* 35 (4), 677–691 e10. [PubMed: 30991027]
51. Liu Y. et al. (2021) Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. *Cell Metab* 33 (6), 1221–1233 e11. [PubMed: 33910046]
52. Dolbois A. et al. (2021) 1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors. *Journal of Medicinal Chemistry* 64 (17), 12738–12760. [PubMed: 34431664]
53. Huff S. et al. (2021) m(6)A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells. *ACS Chem Biol* 16 (2), 324–333. [PubMed: 33412003]
54. Cui Q. et al. (2017) m(6)A RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. *Cell Rep* 18 (11), 2622–2634. [PubMed: 28297667]
55. Lv D. et al. (2022) PDGF signaling inhibits mitophagy in glioblastoma stem cells through N(6)-methyladenosine. *Dev Cell* 57 (12), 1466–1481 e6. [PubMed: 35659339]
56. Tang YJ et al. (2021) m(6)A-Atlas: a comprehensive knowledgebase for unraveling the N-6-methyladenosine (m(6)A) epitranscriptome. *Nucleic Acids Research* 49 (D1), D134–D143. [PubMed: 32821938]
57. Liu S. et al. (2023) M6AREG: m6A-centered regulation of disease development and drug response. *Nucleic Acids Res* 51 (D1), D1333–D1344. [PubMed: 36134713]
58. Tsagkogeorga G. et al. (2022) Predicting genes associated with RNA methylation pathways using machine learning. *Commun Biol* 5 (1), 868. [PubMed: 36008532]
59. Pun FW et al. (2023) AI-powered therapeutic target discovery. *Trends Pharmacol Sci* 44 (9), 561–572. [PubMed: 37479540]

60. Vamathevan J. et al. (2019) Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov* 18 (6), 463–477. [PubMed: 30976107]
61. Jonkhout N. et al. (2017) The RNA modification landscape in human disease. *RNA* 23 (12), 1754–1769. [PubMed: 28855326]
62. Morais P. et al. (2021) The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. *Front Cell Dev Biol* 9, 789427. [PubMed: 34805188]
63. Pardi N. et al. (2017) Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. *Nature* 543 (7644), 248–251. [PubMed: 28151488]
64. Barrangou R and Doudna JA (2016) Applications of CRISPR technologies in research and beyond. *Nat Biotechnol* 34 (9), 933–941. [PubMed: 27606440]
65. Pickar-Oliver A and Gersbach CA (2019) The next generation of CRISPR-Cas technologies and applications. *Nat Rev Mol Cell Biol* 20 (8), 490–507. [PubMed: 31147612]
66. Abudayyeh OO et al. (2017) RNA targeting with CRISPR-Cas13. *Nature* 550 (7675), 280–284. [PubMed: 28976959]
67. Cox DBT et al. (2017) RNA editing with CRISPR-Cas13. *Science* 358 (6366), 1019–1027. [PubMed: 29070703]
68. Chen L. et al. (2022) METTL3-mediated m6A modification stabilizes TERRA and maintains telomere stability. *Nucleic Acids Res* 50 (20), 11619–11634. [PubMed: 36399511]
69. Wilson C. et al. (2020) Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase. *Nat Biotechnol* 38 (12), 1431–1440. [PubMed: 32601430]
70. Xia Z. et al. (2021) Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. *Nucleic Acids Res* 49 (13), 7361–7374. [PubMed: 34181729]
71. Eisenberg E and Levanon EY (2018) A-to-I RNA editing - immune protector and transcriptome diversifier. *Nat Rev Genet* 19 (8), 473–490. [PubMed: 29692414]
72. Ying X. et al. (2020) Programmable N6-methyladenosine modification of CDCP1 mRNA by RCas9-methyltransferase like 3 conjugates promotes bladder cancer development. *Mol Cancer* 19, 1–6. [PubMed: 31901224]
73. Rau K. et al. (2019) Sequence-specific m(6)A demethylation in RNA by FTO fused to RCas9. *RNA* 25 (10), 1311–1323. [PubMed: 31263003]
74. Liu XM et al. (2019) Programmable RNA N(6)-methyladenosine editing by CRISPR-Cas9 conjugates. *Nat Chem Biol* 15 (9), 865–871. [PubMed: 31383972]
75. Adachi H. et al. (2023) Targeted pseudouridylation: An approach for suppressing nonsense mutations in disease genes. *Mol Cell* 83 (4), 637–651 e9. [PubMed: 36764303]
76. Song J. et al. (2023) CRISPR-free, programmable RNA pseudouridylation to suppress premature termination codons. *Mol Cell* 83 (1), 139–155 e9. [PubMed: 36521489]
77. Katrekar D. et al. (2022) Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. *Nat Biotechnol* 40 (6), 938–945. [PubMed: 35145312]
78. Shi H. et al. (2022) Inducible and reversible RNA N(6)-methyladenosine editing. *Nat Commun* 13 (1), 1958. [PubMed: 35414049]
79. Wettengel J. et al. (2017) Harnessing human ADAR2 for RNA repair - Recoding a PINK1 mutation rescues mitophagy. *Nucleic Acids Res* 45 (5), 2797–2808. [PubMed: 27907896]
80. Rauch S. et al. (2018) Targeted m(6)A Reader Proteins To Study Epitranscriptomic Regulation of Single RNAs. *J Am Chem Soc* 140 (38), 11974–11981. [PubMed: 30183280]
81. Fu Y and Zhuang X (2020) m(6)A-binding YTHDF proteins promote stress granule formation. *Nat Chem Biol* 16 (9), 955–963. [PubMed: 32451507]
82. Khong A. et al. (2022) Limited effects of m(6)A modification on mRNA partitioning into stress granules. *Nat Commun* 13 (1), 3735. [PubMed: 35768440]
83. Ries RJ et al. (2023) m(6)A governs length-dependent enrichment of mRNAs in stress granules. *Nat Struct Mol Biol* 30 (10), 1525–1535. [PubMed: 37710015]
84. Konermann S. et al. (2018) Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. *Cell* 173 (3), 665–676 e14. [PubMed: 29551272]

85. Shi H. et al. (2018) m(6)A facilitates hippocampus-dependent learning and memory through YTHDF1. *Nature* 563 (7730), 249–253. [PubMed: 30401835]
86. Dou X. et al. (2023) RBFOX2 recognizes N(6)-methyladenosine to suppress transcription and block myeloid leukaemia differentiation. *Nat Cell Biol* 25 (9), 1359–1368. [PubMed: 37640841]
87. Liu Y. et al. (2016) Targeting cellular mRNAs translation by CRISPR-Cas9. *Sci Rep* 6, 29652. [PubMed: 27405721]
88. Gaudelli NM et al. (2020) Directed evolution of adenine base editors with increased activity and therapeutic application. *Nat Biotechnol* 38 (7), 892–900. [PubMed: 32284586]
89. Lyu J. et al. (2019) Ultra-large library docking for discovering new chemotypes. *Nature* 566 (7743), 224–229. [PubMed: 30728502]
90. Patil DP et al. (2018) Reading m(6)A in the Transcriptome: m(6)A-Binding Proteins. *Trends in Cell Biology* 28 (2), 113–127. [PubMed: 29103884]
91. Shafik AM et al. (2022) Epitranscriptomic dynamics in brain development and disease. *Mol Psychiatry* 27 (9), 3633–3646. [PubMed: 35474104]
92. Livneh I. et al. (2020) The m(6)A epitranscriptome: transcriptome plasticity in brain development and function. *Nat Rev Neurosci* 21 (1), 36–51. [PubMed: 31804615]
93. Vissers C. et al. (2020) The epitranscriptome in stem cell biology and neural development. *Neurobiol Dis* 146, 105139. [PubMed: 33065280]
94. Zhang F. et al. (2023) Epitranscriptomic regulation of cortical neurogenesis via Mettl8-dependent mitochondrial tRNA m(3)C modification. *Cell Stem Cell* 30 (3), 300–311 e11. [PubMed: 36764294]
95. Edens BM et al. (2019) FMRP Modulates Neural Differentiation through m(6)A-Dependent mRNA Nuclear Export. *Cell Rep* 28 (4), 845–854 e5. [PubMed: 31340148]
96. Yoon KJ et al. (2017) Temporal Control of Mammalian Cortical Neurogenesis by m(6)A Methylation. *Cell* 171 (4), 877–889 e17. [PubMed: 28965759]
97. Xu H. et al. (2020) m(6)A mRNA Methylation Is Essential for Oligodendrocyte Maturation and CNS Myelination. *Neuron* 105 (2), 293–309 e5. [PubMed: 31901304]
98. Cheng Y. et al. (2023) Epigenetic and epitranscriptomic regulation of axon regeneration. *Mol Psychiatry* 28 (4), 1440–1450. [PubMed: 36922674]
99. Weng YL et al. (2018) Epitranscriptomic m(6)A Regulation of Axon Regeneration in the Adult Mammalian Nervous System. *Neuron* 97 (2), 313–325 e6. [PubMed: 29346752]
100. Piperi C. et al. (2023) Deciphering glioma epitranscriptome: focus on RNA modifications. *Oncogene* 42 (28), 2197–2206. [PubMed: 37322070]
101. Zhao F. et al. (2021) METTL3-dependent RNA m(6)A dysregulation contributes to neurodegeneration in Alzheimer's disease through aberrant cell cycle events. *Mol Neurodegener* 16 (1), 70. [PubMed: 34593014]
102. Castro-Hernandez R. et al. (2023) Conserved reduction of m(6)A RNA modifications during aging and neurodegeneration is linked to changes in synaptic transcripts. *Proc Natl Acad Sci U S A* 120 (9), e2204933120. [PubMed: 36812208]
103. Flamand MN and Meyer KD (2022) m6A and YTHDF proteins contribute to the localization of select neuronal mRNAs. *Nucleic Acids Res* 50 (8), 4464–4483. [PubMed: 35438793]
104. Martinez De La Cruz B. et al. (2021) Modifying the m(6)A brain methylome by ALKBH5-mediated demethylation: a new contender for synaptic tagging. *Mol Psychiatry* 26 (12), 7141–7153. [PubMed: 34663904]
105. Madugalle SU et al. (2023) Synapse-enriched m6A-modified Malat1 interacts with the novel m6A reader, DPYSL2, and is required for fear-extinction memory. *Journal of Neuroscience*.
106. Hodge RD et al. (2019) Conserved cell types with divergent features in human versus mouse cortex. *Nature* 573 (7772), 61–68. [PubMed: 31435019]
107. Li L and Shi Y (2020) When glia meet induced pluripotent stem cells (iPSCs). *Mol Cell Neurosci* 109, 103565. [PubMed: 33068719]
108. Shi Y. et al. (2017) Induced pluripotent stem cell technology: a decade of progress. *Nat Rev Drug Discov* 16 (2), 115–130. [PubMed: 27980341]

109. Cerneckis J. et al. (2023) Pushing the boundaries of brain organoids to study Alzheimer's disease. Trends Mol Med.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Box 1:**RNA modifications and effector proteins**

RNA molecules are highly decorated by chemical modifications that comprise the epitranscriptome and impart structural and functional properties to the modified transcripts[5, 7]. *N*⁶-methyladenosine (m⁶A) is the most studied RNA modification that dynamically and reversibly decorates multiple RNA species and plays important roles in downstream RNA processing[5]. Dedicated m⁶A modification machinery comprised of m⁶A writer, eraser and reader proteins orchestrates m⁶A installation, removal, and integration into downstream biological processes, respectively (see Figure I). The m⁶A modification is installed by methyltransferase-like (METTL)3/14 and METTL16 writer proteins that use S-adenosylmethionine (SAM) as a methyl donor, whereas demethylation of m⁶A is mediated by FTO and alkB homolog (ALKBH)5 oxygenases[5]. Several m⁶A reader proteins, including those of YT521-B homology (YTH) domain, insulin-like growth factor (IGF), and heterogeneous nuclear ribonucleoprotein (HNRNP) families, recognize m⁶A and regulate RNA processing, such as its nuclear export, translation, and decay[5, 90]. The m⁶A epitranscriptome is dynamically regulated in response to environmental stimuli and cellular stress, thus fine-tuning gene expression in a changing environment. Furthermore, m⁶A has been implicated in cardinal biological processes, including development, tissue homeostasis, and disease[5]. For example, the m⁶A epitranscriptome becomes dysregulated in cancer, contributing to pro-tumorigenic gene expression programs that drive tumor progression[9, 42]. Therefore, therapeutic targeting of the m⁶A modification machinery is an emerging approach to treat various types of cancer, such as leukemia and glioblastoma[9, 42, 54]. Beyond m⁶A, over 170 RNA modifications have been described across the transcriptome[7]. Rapid development of RNA modification detection methods has enabled probing the roles of numerous RNA modifications in cell biology. For example, pseudouridine (Ψ), an isomer of uridine, is often considered to be the fifth RNA nucleotide, given its ubiquitous presence on RNA, and is installed by Ψ synthases (PUS)[1]. However, no Ψ eraser proteins have been identified, and thus it remains unclear whether Ψ can be installed reversibly. Nonetheless, Ψ affects multiple aspects of RNA processing, such as splicing and translation, whereas dysregulation of the Ψ epitranscriptome is evident in cancer[1]. We have recently shown that increased expression of PUS7 leads to aberrant pseudouridylation of transfer RNA (tRNA) in glioblastoma stem cells (GSCs), promoting their proliferation and tumor growth[47]. On the other hand, pharmacological inhibition of PUS7 with a small-molecule compound C17 suppresses GSC proliferation *in vitro* and glioblastoma progression *in vivo*[47]. Overall, the dynamic epitranscriptome regulates most aspects of RNA biology to influence gene expression.

Box 2:**New frontiers: brain epitranscriptomics**

Streamlined detection of RNA modifications, especially m⁶A, has fueled investigation into their roles in human development, homeostasis, and diseases beyond cancer. Brain epitranscriptomics is an excellent case study exemplifying the expansive growth of the RNA modification field and the importance of the epitranscriptome in complex biological processes[91-93]. Given the incredible complexity of the human brain, studying the epitranscriptome provides an opportunity to identify novel regulators of brain function and dysfunction. Indeed, the field of brain epitranscriptomics has attracted substantial interest in recent years, and RNA modifications have been implicated in neurogenesis[94-96], gliogenesis[97], learning and memory[85], neuronal injury[98, 99], gliomas[47, 54, 100], neurodegenerative diseases[101], and other processes (reviewed in[91-93]).

The emerging tools for advanced detection and engineering of RNA modifications discussed in this review can be applied to gain new insights into brain epitranscriptomics. For example, spatiotemporal profiling of RNA modifications at single-cell resolution may reveal yet uncharacterized heterogeneity of the developing human brain, improve neuron cell subtyping, and clarify the mechanisms of neurogenic-to-gliogenic transition. Similarly, characterizing how the epitranscriptome deteriorates in aging may reveal distinct contributions of RNA modifications to the onset and progression of neurodegenerative diseases, such as Alzheimer's disease, and expose targetable cellular pathways for therapeutic development[101, 102]. Accumulating evidence also indicates a prominent role that RNA modifications play in faithful RNA trafficking and localization to distal synapses during neurogenesis, synaptogenesis, and memory formation[103-105]. CRISPR/Cas-based tools for RNA engineering and RNA tracking can be applied to study RNA trafficking in these processes to uncover modification-dependent regulatory mechanisms.

Finally, the study of brain epitranscriptomics can greatly benefit from using cellular models of human origin, given substantial species-specific divergence between human and rodent brains[106]. Human pluripotent stem cell (hPSCs), including embryonic stem cells (ESCs) and induced PSCs (iPSCs), can be used to derive neuronal and non-neuronal human brain cells to study human-specific regulatory mechanisms and phenotypes affected by RNA modifications *in vitro*[107, 108]. Furthermore, hPSCs can be differentiated into three-dimensional brain organoids, multicellular assemblies of neural cells that partially recapitulate human brain development and diseases[109]. Brain organoids have successfully been applied to study the roles of m⁶A[96] and m³C[94] in human brain development, revealing a critical role of RNA modifications in neurogenesis. Overall, scientific discovery in the field of brain epitranscriptomics fueled by technological developments is poised to reveal new insights into the complexity of the human brain.

Outstanding Questions

How is m⁶A stoichiometry regulated at individual modification sites and how does it affect RNA processing?

What are the functional roles of m⁶A clusters?

Are all m⁶A sites equally important on mRNAs that contain multiple m⁶A sites?

How do different RNA modifications interplay to regulate downstream RNA processing?

How are RNA modifications distributed across different isoforms of the same transcript?

What are the species-specific differences in the RNA epitranscriptome of rodents and humans?

Can single-cell profiling of RNA modifications reveal yet uncharacterized heterogeneity of developmental programs or tumor evolution?

Can RNA modification engineering be applied therapeutically for targeted correction of detrimental modification sites?

Can RNA modification engineering be applied to influence intracellular mRNA trafficking for targeted delivery of mRNA transcripts to distinct cellular compartments?

Highlights

Advanced detection of RNA modifications, especially *N*⁶-methyladenosine, paves the way for transcriptome-wide, single-cell, and stoichiometric modification profiling at single-nucleotide resolution

RNA modification databases, tumor atlases, drug-like compound libraries, and machine learning have accelerated therapeutic development focused on epitranscriptomics

Novel RNA modification engineering tools based on the CRISPR/Cas technology or endogenous RNA modification machinery can be applied to uncover causal relationships between individual modification sites and phenotypic outcomes




Figure 1: Methods for high-throughput detection of N^6 -methyladenosine (m^6A).

(A) Protocols for m^6A detection using m^6A -specific antibodies (m^6A -seq and MeRIP-seq) were first reported in 2012. Although m^6A -seq and MeRIP-seq achieve 100–200 nucleotide resolution of mapping m^6A , cross-linking of m^6A -specific antibodies to their RNA targets using a modified protocol (miCLIP) enables m^6A detection at higher resolution. (B) Antibody-free m^6A detection using DART-seq is based on recruitment of a cytidine deaminase to m^6A sites to induce a mutational signature that can later be used to infer the m^6A position. Recently, DART-seq has also been combined with single-cell RNA sequencing (scRNA-seq) for detecting m^6A in single cells (scDART-seq). (C) Chemical and metabolic labeling of m^6A can be used to enrich m^6A -decorated RNA fragments (m^6A -SEAL) or induce a mutational signature around the m^6A site during reverse transcription (m^6A -label-seq and m^6A -SAC-seq). (D) m^6A -sensitive endoribonuclease MazF digests RNA at the ACA but not m^6ACA motif and is used in m^6A -REF-seq and MAZTER-seq protocols of m^6A detection. (E) Recently developed protocols for selective adenosine but not m^6A deamination enable transcriptome-wide stoichiometric m^6A detection, reminiscent of bisulfite sequencing of DNA methylation. (F) Third-generation direct RNA sequencing can be used to detect m^6A and other RNA modifications on native RNA by comparative analysis of modified and unmodified transcripts or by supervised learning.




Figure 2: Therapeutic development focused on epitranscriptomics.

Dysregulation of the epitranscriptome in cancer and other diseases often stems from aberrant expression and function of associated RNA modification enzymes that can be targeted pharmacologically to reverse disease-associated phenotypes. (A) Therapeutic development begins at the stage of target identification, which has been greatly facilitated by tumor atlases that can be used to identify aberrantly expressed RNA modification machinery in cancer. RNA modification databases, such as MODOMICS, m⁶A-Atlas, and M6AREG, can be used to generate testable hypotheses regarding the mode of action of a particular RNA modification enzyme. (B) Having identified a target of interest, virtual drug screening is performed to uncover potential hit compounds. Drug-like compound libraries, such as the library curated by the National Cancer Institute Developmental Therapeutics Program (NCI-DTP) facilitate virtual screening and subsequent acquisition of selected compounds. (C) Identified hit compounds are tested using cell-free assays to characterize target-ligand interactions and evaluate drug inhibitory activity. (D) The hit compound can be further optimized by rational chemical optimization and synthesized for testing *in vitro* and *in vivo*. (E, F) Tumor cell growth assays can be used to assess the effects of the hit compound on cancer cell proliferation and cancer stem cell activity *in vitro*, whereas pharmacokinetics of the hit compound and its effects on tumor growth and survival can be assessed *in vivo*.




Figure 3: Molecular tools for engineering RNA modifications.

(A) CRISPR/Cas technology enables sequence-specific targeting of RNA molecules by Cas endonucleases that recruit protein modalities for RNA modification. Catalytically inactive Cas13 (dCas13) or the RCas9 system that combines dCas9 and a single-stranded DNA monomer containing a protospacer adjacent motif (PAMmer) can be fused to catalytic domains of METTL3 or ALKBH5 to induce m⁶A methylation and demethylation of RNA targets, respectively. dCas endonucleases can also be used to induce other RNA modifications, such as A-to-I editing, highlighting the versatility of the RNA modification engineering technology. (B) In addition to the CRISPR/Cas-based tools, endogenous RNA modification machinery can be recruited to install pseudouridine (Ψ). Recruitment of the Ψ synthase dyskerin 1 (DKC1) complex (guide small nucleolar ribonucleoprotein, snoRNP) by supplying a specific guide RNA enables targeted pseudouridylation. (C) Temporal control of RNA modification engineering can be achieved by photoinducible dimerization of a dCas endonuclease and an RNA modification machinery component.




Figure 4: Applications of molecular tools to study RNA modifications in various biological processes.

(A) RNA modification engineering facilitates the elucidation of causal relationships between individual RNA modification sites and their downstream effects on RNA processing and phenotypic outcomes. For example, targeted methylation of *CDCP1* messenger RNA enhances its translation and bladder cancer progression. (B) Fluorescently-labeled dCas endonucleases fused to m⁶A reader proteins can be used to study how m⁶A reader proteins orchestrate RNA trafficking and localization in highly complex and elongated cells, such as neurons. (C) Molecular tools for RNA engineering can be packaged into adeno-associated virus (AAV) vectors for delivery *in vivo* to study the roles of RNA modifications in complex biological processes, such as learning and memory or tumor growth and metastasis.




Figure I: The dynamics of N⁶-methyladenosine (m⁶A) RNA modification.

Adenosine moieties of RNA are methylated by m⁶A writer proteins, METTL3/14 and METTL16. The modified m⁶A can either be erased by oxygenases FTO and ALKBH5 or recognized by reader proteins of different protein families that in turn mediate downstream RNA processing. For example, YTHDF1 has been shown to promote m⁶A-decorated messenger RNA (mRNA) translation, whereas YTHDF2 facilitates mRNA degradation.